Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine

Sandra Söderholm, Maria Anastasina, Mohammad Majharul Islam, Janne Tynell, Minna M. Poranen, Dennis H. Bamford, Jakob Stenman, Ilkka Julkunen, Ingrida Šauliene, Jef K. De Brabander, Sampsa Matikainen, Tuula A. Nyman, Xavier Saelens, Denis Kainov

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Influenza A viruses (IAVs) impact the public health and global economy by causing yearly epidemics and occasional pandemics. Several anti-IAV drugs are available and many are in development. However, the question remains which of these antiviral agents may allow activation of immune responses and protect patients against co- and re-infections. To answer to this question, we analysed immuno-modulating properties of the antivirals saliphenylhalamide (SaliPhe), SNS-032, obatoclax, and gemcitabine, and found that only gemcitabine did not impair immune responses in infected cells. It also allowed activation of innate immune responses in lipopolysaccharide (LPS)- and interferon alpha (IFNα)-stimulated macrophages. Moreover, immuno-mediators produced by gemcitabine-treated IAV-infected macrophages were able to prime immune responses in non-infected cells. Thus, we identified an antiviral agent which might be beneficial for treatment of patients with severe viral infections.

Original languageEnglish (US)
Pages (from-to)69-80
Number of pages12
JournalAntiviral Research
StatePublished - Feb 1 2016


  • Antiviral agents
  • Immune responses
  • Influenza A virus
  • Innate immunity
  • Virus-host interaction

ASJC Scopus subject areas

  • Pharmacology
  • Virology


Dive into the research topics of 'Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine'. Together they form a unique fingerprint.

Cite this